Multisystem inflammatory syndrome in children in Coastal Andhra, India

Authors

  • Sai Sunil Kishore Manem Department of Pediatric Intensive Care, Medicover Women and Children Hospitals, Visakahapatnam, India; Department of Pediatrics, Maharajah Institute of Medical Sciences, Vizianagaram, India http://orcid.org/0000-0002-4408-2453
  • Vijay Karri Department of Pediatric Intensive Care, Medicover Women and Children Hospitals, Visakahapatnam, India
  • Rahul Gorantla Department of Pediatric Intensive Care, Medicover Women and Children Hospitals, Visakahapatnam, India
  • Rama Garuda Department of Pediatric Intensive Care, Medicover Women and Children Hospitals, Visakahapatnam, India
  • Anita Tripathy Department of Pediatric Intensive Care, Medicover Women and Children Hospitals, Visakahapatnam, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20221854

Keywords:

MIS-C, Multisystem inflammatory syndrome, COVID, Pediatric

Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C) associated with COVID is a recently emerged disease and there is limited Indian data. We reported the presentation and clinical course of these children.

Methods: All children who had symptoms and signs of MIS-C according to WHO criteria and those positive for SARS-CoV-2, were considered for the study. Clinical features, lab parameters, treatment details and outcome were documented.

Results: 104 children, who had MIS-C during the study period. Out of them, 52 (50%) required respiratory support. Among those who required respiratory support 13 (12%) children required invasive ventilation, 11 (10.5%) children could be managed with noninvasive ventilation, whereas 28 (27%) children required supplemental oxygen. 18 (17%) children had signs of myocarditis and left ventricular dysfunction.  12 (11.5%) children had pulmonary edema and Coronary artery dilatation was present in 4(4%) cases. Steroids were used as main stay of therapy. Low dose intravenous methylprednisolone was administered to72(69%); pulse dose methylprednisolone was administered to 12 (12%) children. Intravenous immunoglobulins (IVIG) administered to 20 (19%) children. Among the study group, 103 children survived and one child expired (0.96%).

Conclusions: Optimal use of immunomodulators and frequent hemodynamic assessment with functional ECHO to optimize the inotropes, can improve the outcomes among those with myocardial dysfunction.

Metrics

Metrics Loading ...

References

CDC COVID-19 Response Team. Coronavirus disease 2019 in children-United States, February 12-April 2, 2020. Morb Mortal.Wkly Rep. 2020;69:422-6.

Parri N, Lenge M, Buonsenso D. Children with COVID-19 in Pediatric Emergency Departments in Italy. N Engl J Med. 2020.

Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet; 2020.

Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciu_reda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet; 2020.

Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Available at: www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally- associated-covid-19.

Centers for Disease Control and Prevention. Emergency preparedness and response: health alert network. Published May 14, 2020. Available at: emergency.cdc.gov/han/2020/han00432.asp. Accessed on 5 August 2020.

World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Available at: www.who.int/publicationsdetail/multisystem-inflammatory-syndrome-in-children-and-adolescents-withcovid-19. Published 15 May 2020.

McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation. 2017;135:e927-99.

McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, et al. Pediatric Heart Network Investigators. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation. 2007;116:174-9.

Johns Hopkins University and Medicine. Coronavirus resource center. Coronavirus. Available at: jhu.edu/map.html.

Castagnoli R, Votto M, Licari A. Severe acute respiratory syndrome coronavirus.

2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020:1467.

Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383:347-58.

Levin M. Childhood Multisystem Inflammatory Syndrome - A New Challenge in the Pandemic. N Engl J Med. 2020;383(4):393-5.

Waltuch T, Gill P, Zinns LE, Whitney R, Tokarski J, Tsung JW, et al. Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department. Am J Emerg Med. 2020;38(10):2246.e3-2246.e6.

Godfred-Cato S, Bryant B, Leung J. COVID-19-associated multisystem inflammatory syndrome in children-United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020:7.

Riollano-Cruz M, Akkoyun E, Briceno-Brito E. multisystem inflammatory syndrome in children (mis-c) related to COVID-19: a New York City experience. J Med Virol; 2020.

Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine. 2020;26:100527.

Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324:259-69.

Kil HR, Yu JW, Lee SC, Rhim JW, Lee KY. Changes in clinical and laboratory features of Kawasaki disease noted over time in Daejeon, Korea. Pediatr Rheumatol Online J. 2017;15(1):60.

Belhadjer Z, M_eot M, Bajolle F. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2. Circulation. 2020;142:429-36.

Dasgupta K, Finch SE. A case of pediatric multisystem inflammatory syndrome temporally associated with COVID-19 in South Dakota. S D Med. 2020;73:246-51.

Jain S, Sen S, Lakshmivenkateshiah S, Bobhate P, Venkatesh S, Udani S, et al. Multisystem Inflammatory Syndrome in Children With COVID-19 in Mumbai, India. Indian Pediatr. 2020;57:1015-9.

Dhanalakshmi K, Venkataraman A, Balasubramanian S, Madhusudan M, Amperayani S, Putilibai S, et al. Epidemiological and clinical profile of pediatric inflammatory multisystem syndrome - temporally associated with SARSCoV- 2 (PIMS-TS) in Indian children. Indian Pediatr. 2020;57:1010-4.

Acharyya BC, Acharyya S, Das D. Novel coronavirus mimicking Kawasaki disease in an infant. Indian Pediatr. 2020;57(8):753-4.

Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334-6.

Puntmann VO, Carerj ML, Wieters I. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1265-73.

Nguyen Y, Corre F, Honsel V. A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area. Ann Med. 2020;52:367-75.

Downloads

Published

2022-07-25

How to Cite

Manem, S. S. K., Karri, V., Gorantla, R., Garuda, R., & Tripathy, A. (2022). Multisystem inflammatory syndrome in children in Coastal Andhra, India. International Journal of Contemporary Pediatrics, 9(8), 725–730. https://doi.org/10.18203/2349-3291.ijcp20221854

Issue

Section

Original Research Articles